# CVS HEALTH Corp: Form 10-Q for the period ended Sep 30, 2013

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2013-11-05
- Accepted by EDGAR: Nov 5, 2013, 16:08 ET
- Period: 2013-09-30
- Accession: 0000064803-13-000027
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000006480313000027/cvs20130930-10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000006480313000027/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-07-01 to 2013-09-30 | $31.97bn | us-gaap:Revenues |
| Revenue | 9 months, 2013-01-01 to 2013-09-30 | $93.98bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2013-07-01 to 2013-09-30 | $25.93bn | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2013-01-01 to 2013-09-30 | $76.53bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2013-07-01 to 2013-09-30 | $6.04bn | us-gaap:GrossProfit |
| Gross profit | 9 months, 2013-01-01 to 2013-09-30 | $17.45bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2013-07-01 to 2013-09-30 | $2.16bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2013-01-01 to 2013-09-30 | $5.83bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-07-01 to 2013-09-30 | $125.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2013-01-01 to 2013-09-30 | $379.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2013-07-01 to 2013-09-30 | $779.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2013-01-01 to 2013-09-30 | $2.12bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2013-07-01 to 2013-09-30 | $1.25bn | us-gaap:ProfitLoss |
| Net income | 9 months, 2013-01-01 to 2013-09-30 | $3.33bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2013-07-01 to 2013-09-30 | $1.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2013-01-01 to 2013-09-30 | $2.70 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2013-07-01 to 2013-09-30 | $1.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2013-01-01 to 2013-09-30 | $2.72 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2013-07-01 to 2013-09-30 | 1,226,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2013-01-01 to 2013-09-30 | 1,234,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2013-01-01 to 2013-09-30 | $4.25bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2013-01-01 to 2013-09-30 | $1.33bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2013-01-01 to 2013-09-30 | $829.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months, 2013-01-01 to 2013-09-30 | $2.27bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2013-09-30 | $1.50bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-09-30 | $21.43bn | us-gaap:AssetsCurrent |
| Total assets | at 2013-09-30 | $67.81bn | us-gaap:Assets |
| Current liabilities | at 2013-09-30 | $15.10bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2013-09-30 | $8.82bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2013-09-30 | $572.0m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2013-09-30 | $814.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2013-09-30 | $38.53bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Market risk

As filed, 608 characters.

As of September 30, 2013, the Company did not have any interest rate, foreign currency exchange rate or commodity derivative instruments in place and believes that as of September 30, 2013 its exposure to interest rate risk (inherent in the Company's debt portfolio), foreign currency exchange rate risk and commodity price risk is not material. Effective October 1, 2013, the Company entered into an accelerated share repurchase agreement, which subjects it to some equity price risk. See discussion of the accelerated share repurchase agreement in Note 4 to the condensed consolidated financial statements.

## Controls and procedures

As filed, 3,561 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of September 30, 2013, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to provide reasonable assurance that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or

Rule 15d-15 that occurred in the three months ended September 30, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Part II Item 1

### Legal Proceedings

Certain legal proceedings in which we are involved are discussed in Part I, Item 3 of our 2012 Annual Report on Form 10-K. The following discussion is limited to certain recent developments concerning our legal proceedings and should be read in conjunction with those earlier reports.

1\. A purported shareholder derivative action was filed on behalf of nominal defendant CVS Caremark Corporation against certain of the Company's officers and members of its Board of Directors. The action, which alleges a single claim for breach of fiduciary duty relating to the Company's alleged failure to properly implement internal regulatory controls to comply with the Controlled Substances Act and the Combat Methamphetamine Epidemic Act, was originally filed in June 2012. In addition, an amended complaint was filed in November 2012 and a Supplemental Complaint was filed in April 2013. In October 2013, the court granted the Company's motion to dismiss and entered judgment dismissing the action, without prejudice. Following dismissal of the action, the same purported shareholder sent a letter to the Company's Board of Directors demanding that the Board investigate her allegations and pursue legal action against certain directors and officers of the Company. The Board of Directors intends to review and respond to the letter as appropriate.

### Part II Item 2

### Unregistered Sales of Equity Securities and Use of Proceeds

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended September 30, 2013, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2012 Repurchase Program. See Note 4 to the condensed consolidated financial statements.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| July 1, 2013 through July 31, 2013 | — | $— | — | $3,921,114,509 |
| August 1, 2013 through August 31, 2013 | 11,773,386 | $58.82 | 11,773,386 | $3,228,546,869 |
| September 1, 2013 through September 30, 2013 | 14,061,790 | $59.12 | 14,061,790 | $2,397,249,904 |
| Totals | 25,835,176 |  | 25,835,176 |  |

36

### Part II Item 6

### Exhibits

Filed Nov 5, 2013.
Source: SEC EDGAR, the filing index for accession 0000064803-13-000027. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
